Key Highlights

  • Starling Oncology shares are trading up 28.23% today, extending an after-hours surge from a day earlier.
  • Second-quarter revenue reached $161.3 million, up 34.6% year-over-year and ahead of the $155.3 million estimate.
  • Adjusted EBITDA of $2.0 million beat estimates and marked the company's second consecutive quarter of positive adjusted EBITDA.
  • Management raised full-year 2026 guidance and lifted its revenue outlook to a range of $650 million to $670 million.

What's Driving Starling Oncology's Rally?

Starling Oncology (NASDAQ:STLN), formerly known as The Oncology Institute before its August 2026 rebrand, is surging today as investors continue to digest a strong second-quarter earnings report released the prior afternoon. Revenue rose 34.6% year-over-year to $161.3 million, topping the $155.3 million estimate by more than 3%, while gross profit jumped 55.2% to $27.2 million. Adjusted EBITDA came in at $2.0 million, beating expectations and improving from a loss in the prior-year period, marking the company's second consecutive quarter of positive adjusted EBITDA.

Starling Oncology is a value-based oncology group operating an integrated community-based cancer care platform through three segments: Specialty Pharmacy, Patient Services, and Clinical Trials & Other, serving approximately 2.1 million patients across five states.

Raised Guidance and Balance Sheet Progress

Management raised full-year 2026 guidance, lifting its revenue outlook to a range of $650 million to $670 million and its adjusted EBITDA guidance to a range of $2 million to $7 million, while also flagging positive free cash flow guidance of $5 million to $1.5 million. The company also completed a strategic refinancing with Orbimed in July, replacing an $86 million term loan with a $75 million convertible note and roughly $11 million in cash, extending debt maturities from 2027 to 2031 without equity dilution.

Investors appear to be responding positively to the combination of accelerating growth and improving profitability in the value-based oncology space, a theme that has also lifted shares of specialty pharmacy peers Personalis (NASDAQ:PSNL) and GeneDx Holdings (NASDAQ:WGS) this week.

Conclusion

Starling Oncology's shares are rallying today as the market continues to reward a strong second-quarter beat, raised full-year guidance, and a refinancing deal that extends the company's runway. The results and the rebrand from The Oncology Institute earlier this month appear to be building investor enthusiasm for the company's value-based cancer care model.

This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.